Antibody drug conjugates (ADC’s) are promising and effective anticancer medications employed for efficient treatment of cancer patients. ADC’s are biopharmaceutical drugs prepared by integrating two clinical approaches viz cell killing HPAPI (powerful pharmaceutical ingredient) and monoclonal antibody specificity. This combination approach enables elimination of cancer infected cells without harming healthy cells in patient’s body. The report segments the market based on drugs, technology, mechanism of action, application and region. Based on drug market is bifurcated into Adcetris and Kadcyla. By technology type, it is segmented into payload, monoclonal antibodies, and type of linker. Based on mechanism of action, it is divided into CD30 antibodies and HER2 antibodies. Based on application, the market is divided into breast cancer, Lymphoma, and other types of cancer. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

CHAPTER 1 INTRODUCTION

CHAPTER 2 EXECUTIVE

CHAPTER 3 MARKET

CHAPTER 4 ANTIBODY DRUG CONJUGATES MARKET, BY DRUG

CHAPTER 5 ANTIBODY DRUG CONJUGATES MARKET, BY MECAHNISM OF ACTION

CHAPTER 6 ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION

CHAPTER 7 ANTIBODY DRUG CONJUGATES MARKET, BY REGION

CHAPTER 8 COMPANY PROFILES